These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


265 related items for PubMed ID: 29734146

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K.
    BMC Nephrol; 2019 Aug 02; 20(1):293. PubMed ID: 31375087
    [Abstract] [Full Text] [Related]

  • 31. Rituximab in steroid-dependent nephrotic syndrome.
    El Koumi M.
    Iran J Kidney Dis; 2013 Nov 02; 7(6):502-6. PubMed ID: 24241100
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E, Champion K, Kronbichler A, Lightstone L, Jayne D, Wilson E, Griffith M.
    BMC Nephrol; 2024 Aug 07; 25(1):253. PubMed ID: 39112932
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A case of minimal change nephrotic syndrome complicated by Kimura disease treated with rituximab.
    Yoshida R, Hara Y, Fujii Y, Matuda H.
    CEN Case Rep; 2023 Nov 07; 12(4):368-373. PubMed ID: 36809634
    [Abstract] [Full Text] [Related]

  • 36. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A, König P, Busch M, Wolf G, Mayer G, Rudnicki M.
    Wien Klin Wochenschr; 2013 Jun 07; 125(11-12):328-33. PubMed ID: 23624956
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS.
    Nephrology (Carlton); 2019 Dec 07; 24(12):1241-1247. PubMed ID: 30586217
    [Abstract] [Full Text] [Related]

  • 39. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, Praga M, Ballarín J, Díaz-Encarnación M, Spanish Group for the Study of Glomerular Diseases (GLOSEN).
    BioDrugs; 2017 Jun 07; 31(3):239-249. PubMed ID: 28534103
    [Abstract] [Full Text] [Related]

  • 40. [Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult. Multicenter study of 32 patients].
    Pruna A, Barka A, Nochy D, Hauet T, Boulanger H, Landais P.
    Nephrologie; 1997 Jun 07; 18(3):95-101. PubMed ID: 9297136
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 14.